These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 23738435

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ.
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [Abstract] [Full Text] [Related]

  • 3. Diagnosis and treatment of Wilson's disease.
    Subramanian I, Vanek ZF, Bronstein JM.
    Curr Neurol Neurosci Rep; 2002 Jul; 2(4):317-23. PubMed ID: 12044251
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The link between copper and Wilson's disease.
    Purchase R.
    Sci Prog; 2013 Jul; 96(Pt 3):213-23. PubMed ID: 24244969
    [Abstract] [Full Text] [Related]

  • 8. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
    Brewer GJ.
    CNS Drugs; 2005 Jul; 19(3):185-92. PubMed ID: 15740174
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?
    Schilsky ML.
    Curr Gastroenterol Rep; 2001 Feb; 3(1):54-9. PubMed ID: 11177695
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT.
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [Abstract] [Full Text] [Related]

  • 12. Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.
    Deguchi K, Sasaki I, Touge T, Tsukaguchi M, Ikeda K, Shimamura M, Urai Y, Watanabe S, Takeuchi H, Kuriyama S.
    J Neurol; 2005 Apr; 252(4):495-7. PubMed ID: 15726258
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [The onset of psychiatric disorders and Wilson's disease].
    Benhamla T, Tirouche YD, Abaoub-Germain A, Theodore F.
    Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
    Morita J, Yoshino M, Watari H, Yoshida I, Motohiro T, Yamashita F, Okano Y, Hashimoto T.
    Dev Pharmacol Ther; 1992 Dec; 19(1):6-9. PubMed ID: 1307347
    [Abstract] [Full Text] [Related]

  • 18. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
    Farinati F, Cardin R, D'inca R, Naccarato R, Sturniolo GC.
    J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Wilson's disease.
    Ferenci P.
    Clin Liver Dis; 1998 Feb; 2(1):31-49, v-vi. PubMed ID: 15560044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.